Axillary Mass

The initial differential diagnosis for a palpable axillary mass in an adult female is broad, encompassing benign conditions like fibroadenoma, lipoma, lymphadenopathy (reactive or infectious), hidradenitis suppurativa, and more serious conditions like breast cancer metastasis or lymphoma. The workup should begin with a thorough history and physical exam, focusing on characteristics of the mass (size, mobility, tenderness, consistency), associated symptoms (pain, fever, skin changes), and relevant risk factors (family history of breast cancer, recent infections). Imaging plays a crucial role in further clarifying the diagnosis. Ultrasound is often the first-line imaging modality, particularly helpful in differentiating cystic vs. solid masses. Mammography should also be considered, especially in women over 40 or with any breast-related symptoms. If ultrasound or mammography findings are indeterminate, further evaluation with MRI, fine-needle aspiration (FNA) biopsy, or core needle biopsy may be necessary to obtain a definitive diagnosis. Explore how integrating a standardized imaging protocol can improve diagnostic accuracy in axillary mass evaluation.

Axillary lymph node dissection (ALND) is typically indicated in the management of breast cancer when sentinel lymph node biopsy (SLNB) reveals metastatic disease. The presence of positive sentinel nodes suggests a higher risk of further axillary involvement, and ALND helps determine the extent of nodal spread, guiding further treatment decisions (e.g., adjuvant chemotherapy, radiation therapy). However, ALND carries potential complications, including lymphedema, seroma formation, infection, nerve injury (e.g., intercostobrachial nerve), and shoulder dysfunction. The decision to perform ALND must be individualized, carefully weighing the benefits of accurate staging against the potential risks of complications. Consider implementing strategies to mitigate lymphedema risk, such as preoperative lymphatic mapping and minimizing axillary dissection when appropriate. Learn more about the evolving role of ALND in the era of neoadjuvant therapy and personalized breast cancer treatment.

Differentiating benign from malignant axillary lymphadenopathy requires a systematic approach. Benign lymphadenopathy typically presents with tender, mobile nodes, often associated with a local infection or inflammatory process. Malignant nodes, on the other hand, tend to be firm, fixed, non-tender, and may be accompanied by systemic symptoms (e.g., weight loss, night sweats). Clinical presentation alone is often insufficient, and further investigations are crucial. Ultrasound can assess nodal size, shape, and cortical thickness, helping differentiate reactive from suspicious nodes. Fine-needle aspiration (FNA) or core needle biopsy can provide a definitive diagnosis by obtaining tissue for cytological or histological examination. Excisional biopsy may be indicated for persistently enlarged or suspicious nodes that do not yield a diagnosis through less invasive methods. Serum markers (e.g., LDH) and imaging studies (e.g., CT, PET) may be helpful in evaluating systemic involvement in suspected malignancy. Explore how advanced imaging techniques and molecular diagnostics can enhance the accuracy of differentiating benign and malignant axillary lymphadenopathy.